A randomized assessors-blind clinical trial to evaluate the safety and the efficacy of albendazole alone and in combination with mebendazole or pyrantel for the treatment of Trichuris trichiura infection in school-aged children in Lambaréné and surroundings
Helminthiasis remains a public health issue in endemic areas. Various drugs have been proposed to improve efficacy against helminths. The study aimed to assess the safety and efficacy of three different anthelmintic combinations to treat Trichuris trichiura infections. We conducted a randomized assessors-blind clinical trial involving children aged 2-17 years with T. trichiura. Participants were randomly assigned to one of three treatment arms. On the first and third days, all participants got albendazole 400 mg, and on the second day, albendazole (arm A), mebendazole 500 mg (arm B), or pyrantel 125 mg/kg (arm C). We assessed treatment efficacy using the cure rate (CR) and egg reduction rate (ERR) at 3 and 6 weeks post-treatment. At 3 weeks post-treatment, ERR and CR were highest in study arm A [ERR = 94%, 95% confidence interval (CI): 92-95; CR = 71%; 95% CI: 58-81] compared to the B and C arms. Decrease in ERR was significant only for arm B versus arm A (P-value <0.001); decrease in ERR was significant for arms B and C (P-value <0.001). No statistical difference was observed in CR when comparing arms A and B (P-value =1.00) and C (P-value =0.27). At 6 weeks, a decrease in ERR was observed in three arms, significant only for arm C, 81% (95% CI: 78-83). A significant increase in egg counts was observed between 3 and 6 weeks post-treatment. All treatments were safe with mild adverse events. Albendazole 400 mg/day (arm A) showed the highest efficacy against trichuriasis. Nonetheless, this treatment regimen was able to cure half of the treated individuals highlighting concerns about controlling the transmission of T. trichiura.CLINICAL TRIALRegistered at ClinicalTrials.gov (NCT04326868).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Antimicrobial agents and chemotherapy - (2024) vom: 02. Apr., Seite e0121123 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nguema Moure, Paul Alvyn [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Albendazole |
|---|
| Anmerkungen: |
Date Revised 10.04.2024 published: Print-Electronic ClinicalTrials.gov: NCT04326868 Citation Status Publisher |
|---|
| doi: |
10.1128/aac.01211-23 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370532473 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370532473 | ||
| 003 | DE-627 | ||
| 005 | 20240410232837.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240403s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/aac.01211-23 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1371.xml |
| 035 | |a (DE-627)NLM370532473 | ||
| 035 | |a (NLM)38563751 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nguema Moure, Paul Alvyn |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A randomized assessors-blind clinical trial to evaluate the safety and the efficacy of albendazole alone and in combination with mebendazole or pyrantel for the treatment of Trichuris trichiura infection in school-aged children in Lambaréné and surroundings |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04326868 | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Helminthiasis remains a public health issue in endemic areas. Various drugs have been proposed to improve efficacy against helminths. The study aimed to assess the safety and efficacy of three different anthelmintic combinations to treat Trichuris trichiura infections. We conducted a randomized assessors-blind clinical trial involving children aged 2-17 years with T. trichiura. Participants were randomly assigned to one of three treatment arms. On the first and third days, all participants got albendazole 400 mg, and on the second day, albendazole (arm A), mebendazole 500 mg (arm B), or pyrantel 125 mg/kg (arm C). We assessed treatment efficacy using the cure rate (CR) and egg reduction rate (ERR) at 3 and 6 weeks post-treatment. At 3 weeks post-treatment, ERR and CR were highest in study arm A [ERR = 94%, 95% confidence interval (CI): 92-95; CR = 71%; 95% CI: 58-81] compared to the B and C arms. Decrease in ERR was significant only for arm B versus arm A (P-value <0.001); decrease in ERR was significant for arms B and C (P-value <0.001). No statistical difference was observed in CR when comparing arms A and B (P-value =1.00) and C (P-value =0.27). At 6 weeks, a decrease in ERR was observed in three arms, significant only for arm C, 81% (95% CI: 78-83). A significant increase in egg counts was observed between 3 and 6 weeks post-treatment. All treatments were safe with mild adverse events. Albendazole 400 mg/day (arm A) showed the highest efficacy against trichuriasis. Nonetheless, this treatment regimen was able to cure half of the treated individuals highlighting concerns about controlling the transmission of T. trichiura.CLINICAL TRIALRegistered at ClinicalTrials.gov (NCT04326868) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Trichuris trichiura | |
| 650 | 4 | |a albendazole | |
| 650 | 4 | |a benzimidazole combination | |
| 650 | 4 | |a coinfection | |
| 650 | 4 | |a efficacy | |
| 650 | 4 | |a mebendazole | |
| 650 | 4 | |a pyrantel | |
| 650 | 4 | |a safety | |
| 650 | 4 | |a trichuriasis | |
| 700 | 1 | |a Nzamba Maloum, Moustapha |e verfasserin |4 aut | |
| 700 | 1 | |a Manouana, Gédéon Prince |e verfasserin |4 aut | |
| 700 | 1 | |a Laclong Lontchi, Roméo-Aimé |e verfasserin |4 aut | |
| 700 | 1 | |a Mbong Ngwese, Mirabeau |e verfasserin |4 aut | |
| 700 | 1 | |a Edoa, Jean Ronald |e verfasserin |4 aut | |
| 700 | 1 | |a Fréjus Zinsou, Jeannot |e verfasserin |4 aut | |
| 700 | 1 | |a Meulah, Brice |e verfasserin |4 aut | |
| 700 | 1 | |a Mahmoudou, Saidou |e verfasserin |4 aut | |
| 700 | 1 | |a N'noh Dansou, Elsy Mirna |e verfasserin |4 aut | |
| 700 | 1 | |a Josiane Honkpehedji, Yabo |e verfasserin |4 aut | |
| 700 | 1 | |a Romeo Adegbite, Bayode |e verfasserin |4 aut | |
| 700 | 1 | |a Agnandji, Selidji Todagbe |e verfasserin |4 aut | |
| 700 | 1 | |a Ramharter, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Lell, Bertrand |e verfasserin |4 aut | |
| 700 | 1 | |a Borrmann, Steffen |e verfasserin |4 aut | |
| 700 | 1 | |a Kremsner, Peter G |e verfasserin |4 aut | |
| 700 | 1 | |a Dejon-Agobé, Jean Claude |e verfasserin |4 aut | |
| 700 | 1 | |a Adegnika, Ayôla Akim |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Antimicrobial agents and chemotherapy |d 1972 |g (2024) vom: 02. Apr., Seite e0121123 |w (DE-627)NLM000026506 |x 1098-6596 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:02 |g month:04 |g pages:e0121123 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/aac.01211-23 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 02 |c 04 |h e0121123 | ||